These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7206225)

  • 1. [Maintenance therapy with low-dose of melphalan in multiple myeloma (author's transl)].
    Hirasawa Y; Nagaoka T; Kuto F; Tokuhiro H; Kikawada R
    Rinsho Ketsueki; 1980 Nov; 21(11):1646-54. PubMed ID: 7206225
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
    Rubio Felix D; Giraldo MP; Raichs A; García Zueco JC; Mur P; Faura MV; Ruíz-Marcuello E; Piñan MA
    Sangre (Barc); 1980; 25(1):25-34. PubMed ID: 7384962
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple myeloma (author's transl)].
    Nakatsuji T; Matsumoto N; Kaku K; Hiroshige Y; Oda S; Shinohara K; Yaga K; Fujii S; Miwa S; Kamei T; Nagasawa T; Tani S
    Rinsho Ketsueki; 1980 Mar; 21(3):347-55. PubMed ID: 7411874
    [No Abstract]   [Full Text] [Related]  

  • 4. [The treatment of myelomatosis with melphalan (author's transl)].
    Hasegawa M; Aoki M; Ogawa T; Imamura Y; Hino S
    Rinsho Ketsueki; 1977 Aug; 18(8):961-72. PubMed ID: 916219
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sideroblastic anemia in a multiple myeloma treated by melphalan (author's transl)].
    Phelip X; Grosclaude S; Rouge P; Mouries D; Blanc D
    Sem Hop; 1979 Oct 18-25; 55(35-36):1633-5. PubMed ID: 231836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Melphalan therapy in Myelomatosis].
    Ota H; Ikeda Y; Shibata T; Hattori H; Yasuma A
    Rinsho Ketsueki; 1972 Oct; 13(5):811-9. PubMed ID: 4674857
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
    Shustik C; Belch A; Robinson S; Rubin SH; Dolan SP; Kovacs MJ; Grewal KS; Walde D; Barr R; Wilson J; Gill K; Vickars L; Rudinskas L; Sicheri DA; Wilson K; Djurfeldt M; Shepherd LE; Ding K; Meyer RM
    Br J Haematol; 2007 Jan; 136(2):203-11. PubMed ID: 17233817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolonged survival in a case of multiple myeloma treated with high dose of melphalan].
    Shibata T; Ikeda Y; Isobe T; Ota H; Nimi M
    Rinsho Ketsueki; 1973 May; 14(5):619-25. PubMed ID: 4738278
    [No Abstract]   [Full Text] [Related]  

  • 11. [An autopsy case of multiple myeloma with disseminated necrotizing leukoencephalopathy (author's transl)].
    Hirai H; Taketani T; Matsumoto M; Hayakawa K; Kawaguchi A; Mizutani T
    Rinsho Ketsueki; 1981 Oct; 22(10):1565-71. PubMed ID: 7334598
    [No Abstract]   [Full Text] [Related]  

  • 12. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multiple myeloma transforming into acute leukaemia (author's transl)].
    Mayans J; Redon J; Badia L; Herranz C; Calabuig JR; Sanz MA; Soler A; Caballero M; Marty ML
    Sangre (Barc); 1977; 22(6):1026-9. PubMed ID: 601670
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone].
    Sezaki T; Ishii H; Osada T; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1982 Jun; 23(6):847-53. PubMed ID: 7176091
    [No Abstract]   [Full Text] [Related]  

  • 18. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.